Filing Details
- Accession Number:
- 0001415889-22-012089
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-12-05 20:44:07
- Reporting Period:
- 2022-12-02
- Accepted Time:
- 2022-12-05 20:44:07
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1708527 | Aziyo Biologics Inc. | AZYO | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1304079 | Matthew Ferguson | C/O Aziyo Biologics, Inc. 12510 Prosperity Drive, Suite 370 Silver Spring MD 20904 | Chief Financial Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Class A Common Stock | Acquisiton | 2022-12-02 | 6,000 | $4.03 | 23,217 | No | 4 | P | Direct | |
Class A Common Stock | Acquisiton | 2022-12-05 | 20,000 | $4.75 | 43,217 | No | 4 | P | Direct | |
Class A Common Stock | Acquisiton | 2022-12-05 | 2,000 | $3.61 | 45,217 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.00 to $4.05. The reporting person undertakes to provide Aziyo Biologics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.56 to $3.65. Thereporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.